Iconovo reports Q3 quarter with increasing revenues
Net sales increased by 219%, and the company is working on partnerships for ICOres and ICOpre as well as awaiting decision status for Oxytocin financing.
See the latest news and media coverage for Iconovo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Inhalation medicine development company
iconovo.seLast updated
In short: Iconovo reported 219% revenue growth in Q3 and signed a strategic collaboration with Lonza
Net sales increased by 219%, and the company is working on partnerships for ICOres and ICOpre as well as awaiting decision status for Oxytocin financing.
The company finalized a strategic collaboration with Lonza for spray-dried formulations. CEO Anders Månsson was appointed permanently. The organization focuses on securing out-licensing agreements.
Net sales increased to 675 kSEK and the loss decreased to -8 093 kSEK compared to the same period last year.
Reports net sales of 675 TSEK, operating loss of -7,996 TSEK, share issues raising MSEK 49.6, patent progress for ICOpre®, and LOI with Lonza.
Iconovo AB (ICO.ST) released Loss for third quarter of -SEK6.81 million The company's earnings came in at -SEK6.81 million, or -SEK0.07 per share. This compares...
14.04. Iconovo AB: Anders Månsson is appointed CEO 253 GlobeNewswire (Europe) Iconovo AB (publ) has today appointed Anders Månsson as permanent CEO of Iconovo AB...
On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried...
Stockholm, April 6, 2018— Nasdaq (Nasdaq: NDAQ) announces that the trading in Iconovo AB's shares (short name: ICO) will commence today on Nasdaq First North...
Track Iconovo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Iconovo and other trending companies.